Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Massachusetts General Hospital
Study ID
NCT03891615
Phase
PHASE1
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Niraparib — DRUG
    Niraparib is a type of drug called a "PARP inhibitor", which blocks DNA (the genetic material of cells) damage from being repaired or may prevent damage from occurring in the first place. In cancer treatment, inhibiting PARP may help kill cancer cells through deadly DNA damage.
  • Osimertinib — DRUG
    Osimertinib blocks mutated EGFR, which may cause tumor regression (when the tumor starts to shrink) and prevent the spread of the cancer.

Study Details

This research study is studying a combination of drugs as a possible treatment for EGFR-Mutated Advanced Lung Cancer. The names of the study drugs involved in this study are Niraparib and Osimertinib.

Key Dates

First listed
Mar 27, 2019
Start date
Jun 6, 2019
Status verified
Sep 2026
Primary completion
Jul 3, 2024
Completion
Nov 7, 2024

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Niraparib + Osimertinib
    * Niraparib will be administered orally once daily * Osimertinib will be administered by mouth once daily

Primary Outcome Measure

Maximum Tolerated Dose of Niraparib [ Time Frame: 2 years ]

Locations (3)

FacilityCityStateZIPSite coordinators
Beth Israel DeaconessBostonMassachusetts02115-
Dana Farber Cancer InstituteBostonMassachusetts02114-
Massachusetts General Hospital Cancer CenterBostonMassachusetts02114-

Find similar trials in Boston, MA

Nationwide
Lung cancer trialsOncology trialsLung oncology trialsLung disease trials
By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Beth Israel Deaconess· Boston, MADana Farber Cancer Institute· Boston, MAMassachusetts General Hospital Cancer Center· Boston, MA

Related Studies